Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savient's Krystexxa Wins Advisory Cmte. Endorsement

This article was originally published in The Pink Sheet Daily

Executive Summary

In light of a cardiovascular signal but insufficient data, panel recommends a REMS with provider registration for the orphan biologic.

You may also be interested in...



Miles To Go Before Savient Krystexxa Approval; REMS Talks Are Next Step

Now that gout drug candidate Krystexxa has passed muster with FDA's Arthritis Drugs Advisory Committee, its next major hurdle is agency approval. But with only six weeks to go until its Aug. 1 user fee date and what's expected to be a fairly complex Risk Evaluation and Mitigation Strategy, odds are FDA will be unable to meet that timeline

Miles To Go Before Savient Krystexxa Approval; REMS Talks Are Next Step

Now that gout drug candidate Krystexxa has passed muster with FDA's Arthritis Drugs Advisory Committee, its next major hurdle is agency approval. But with only six weeks to go until its Aug. 1 user fee date and what's expected to be a fairly complex Risk Evaluation and Mitigation Strategy, odds are FDA will be unable to meet that timeline

Febuxostat Approval Still Leaves Many Questions For Lively Gout Market

FDA's mid-February approval of Takeda's oral gout drug Uloric (febuxostat) may have come as no surprise, given an advisory panel's positive recommendation in November, but the gout market itself could take some curious turns as therapy models shake out and other candidates line up for approvals

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel